Related references
Note: Only part of the references are listed.Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marina C Garassino et al.
LANCET ONCOLOGY (2020)
The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life
Rebekah Park et al.
JOURNAL OF CANCER SURVIVORSHIP (2020)
Immuno-oncology-the new paradigm of lung cancer treatment
D. E. Dawe et al.
CURRENT ONCOLOGY (2020)
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
Fabrice Barlesi et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck et al.
EUROPEAN JOURNAL OF CANCER (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
Yi-He Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
David Cella et al.
LANCET ONCOLOGY (2019)
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
Rodolfo Bordoni et al.
CLINICAL LUNG CANCER (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
Martin Reck et al.
EUROPEAN JOURNAL OF CANCER (2018)
Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) plus chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Health-related quality of life results from the phase III CheckMate 067 study
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2017)
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
Julie R. Brahmer et al.
LANCET ONCOLOGY (2017)
The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries
Sarah Kleijnen et al.
QUALITY OF LIFE RESEARCH (2017)
Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials
Thomas M. Atkinson et al.
JAMA ONCOLOGY (2017)
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2016)
Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward
Namrata Vijayvergia et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das et al.
JOURNAL OF IMMUNOLOGY (2015)
The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study
Shrividya Iyer et al.
SUPPORTIVE CARE IN CANCER (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Quality of Life and Smoking
Matthew Goldenberg et al.
AMERICAN JOURNAL ON ADDICTIONS (2014)
Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany
Shrividya Iyer et al.
LUNG CANCER (2013)
Patient reported outcomes: looking beyond the label claim
Lynda C. Doward et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
EQ-5D: a measure of health status from the EuroQol Group
R Rabin et al.
ANNALS OF MEDICINE (2001)
Share Paper
